This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
F.N.B. (FNB)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
FNBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Amgen (AMGN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AMGNNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Will SYK's Q2 Earnings Reflect Strong Growth Despite Tariff Overhang?
by Zacks Equity Research
Stryker's second-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs and tariffs are likely to have continued to hurt margins.
SYKNegative Net Change CAHNegative Net Change CORNegative Net Change WGSNegative Net Change
medical medical-devices
Henry Schein to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
HSIC eyes modest Q2 gains, with dental, medical and specialty segments showing signs of steady momentum.
CAHNegative Net Change HSICNegative Net Change CORNegative Net Change EXASNegative Net Change
earnings medical medical-devices
Hologic Focuses on Breast Health Turnaround This Year: Can It Deliver?
by Moumi Mondal
HOLX eyes a Breast Health rebound in Q4, backed by leadership changes, new strategy and Endomag momentum.
HOLXNegative Net Change RDNTNegative Net Change GEHCNegative Net Change
medical medical-devices
Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?
by Urmimala Biswas
Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.
AZNNegative Net Change NVOPositive Net Change NVDANegative Net Change TEMPositive Net Change
artificial-intelligence healthcare medical medical-devices smart-health tech-stocks
HIMS vs. TDOC: Which Direct-to-Consumer Health Stock Wins Now?
by Debanjana Dey
Hims & Hers and Teladoc Health are reshaping virtual care, but which has the edge in earnings growth and strategic expansion? Let's see.
TDOCPositive Net Change HIMSNegative Net Change
medical medical-devices
Baxter Q2 Preview: Can Core Segments Deliver Another Solid Quarter?
by Zacks Equity Research
BAX aims for modest Q2 growth as core segments build on Q1 momentum and margin gains stabilize after recent recovery.
BAXPositive Net Change CAHNegative Net Change CORNegative Net Change WGSNegative Net Change
medical medical-devices
Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings?
by Zacks Equity Research
GEHC leans on Imaging and PDx strength for Q2, but tariff headwinds and margin pressures could test investor confidence.
CAHNegative Net Change CORNegative Net Change GEHCNegative Net Change WGSNegative Net Change
medical medical-devices
RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View
by Zacks Equity Research
Revvity's second-quarter results showcase strong growth in its Diagnostics business, along with recovery in Life Sciences segmental sales.
ALGNPositive Net Change CAHNegative Net Change CORNegative Net Change RVTYPositive Net Change
earnings medical medical-devices
Should You Buy Alphabet Inc. (GOOG) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
GOOGNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus
by Santanu Roy
AU, CAT and HSY are standing out as Zacks' high-conviction picks, with each posting double-digit gains in recent weeks.
ITWNegative Net Change CATPositive Net Change HSYPositive Net Change INTUNo Net Change AUNegative Net Change OPRXPositive Net Change MTDPositive Net Change MTZNegative Net Change APAMNegative Net Change NOBLNegative Net Change NTLAPositive Net Change NNGRYNegative Net Change
computers construction consumer-staples finance gold industrial-products insurance medical medical-devices
ISRG's Gross Margin Falls on Product Transition and Trade Pressures
by Indrajit Bandyopadhyay
Intuitive Surgical's Q2 gross margin declines to 67.9% as product mix shifts, new facility costs and tariffs weigh on profitability.
BSXNegative Net Change ISRGPositive Net Change TMOPositive Net Change
medical medical-devices
IDEXX to Release Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
IDXX eyes a Q2 earnings jump with CAG growth, global pricing gains, and momentum in water and software segments.
CAHNegative Net Change IDXXPositive Net Change CORNegative Net Change WGSNegative Net Change
earnings medical medical-devices
CVS or UnitedHealth: Which Stock Is a Better Buy Ahead of Q2 Earnings?
by Urmimala Biswas
CVS shows resilience with stable insurance margins and capital discipline, while UNH faces cost headwinds and a sharp earnings cut.
UNHNegative Net Change CVSPositive Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report healthcare medical medical-devices retail
Integer Holdings Q2 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
ITGR posts strong second-quarter revenue growth, but EPS misses estimate despite solid segment momentum.
BSXNegative Net Change CAHNegative Net Change CORNegative Net Change ITGRPositive Net Change
earnings medical medical-devices
Raymond James Financial, Inc. (RJF) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
RJFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
CryoPort, Inc. (CYRX) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CYRXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Alphabet (GOOGL) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
GOOGLNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Ur Energy (URG) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
URGNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Envista (NVST)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
NVSTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
OPRX Delivers Solid Q1 Earnings: But Can It Sustain the Momentum?
by Indrajit Bandyopadhyay
OptimizeRx posts 11% Q1 growth and rising EBITDA, but long-term momentum hinges on scaling subscriptions and margin mix gains.
OPRXPositive Net Change HSTMNo Net Change HCATNegative Net Change
medical medical-devices
Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside?
by Indrajit Bandyopadhyay
ISRG's Q2 procedure growth hits 17%, but continuation of EPS growth hinges on easing margin pressure from FX and da Vinci 5 adoption.
ISRGPositive Net Change GMEDNegative Net Change ZBHNegative Net Change
medical medical-devices
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?
by Moumi Mondal
EXAS gains edge over HOLX as rising Cologuard adoption, new launches and bullish EPS trends boost investor appeal.
HOLXNegative Net Change EXASNegative Net Change
medical medical-devices
Can Sustained Strength in Water Drive ECL Stock Before Q2 Earnings?
by Zacks Equity Research
Ecolab rides momentum in Global Water and Pest Elimination, but macroeconomic headwinds may test its second-quarter 2025 earnings strength.
ECLNegative Net Change ESINegative Net Change BCPCNegative Net Change HWKNNegative Net Change
earnings medical medical-devices